›› 2018, Vol. 38 ›› Issue (4): 411-.doi: 10.3969/j.issn.1674-8115.2018.04.010

• Original article (Clinical research) • Previous Articles     Next Articles

Prevalence of pre-existing direct-acting antiviral agents resistance-associated variants in genotype 1HCV/HIV co-infected patients

JIANG Ling-yu1*, LI Yu-nong1*, HU Peng2*, SHE Sha1, ZHANG Zhen-fang1   

  1. 1. Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral, Chongqing Medical University, Chongqing 400016, China;2. Department of Laboratory Medicine, Chengdu Pi County Traditional Chinese Medicine Hospital in Sichuan Province, Chengdu 611730, China
  • Online:2018-04-28 Published:2018-05-03
  • Supported by:
    National Science and Technology Major Project of China,2017ZX10202203-007,2017ZX10202203-008

Abstract: Objective · To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) co-infected patients. Methods · All NS3 and NS5B HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved NCBI GenBank database. And sequences were aligned and analyzed using software MEGA 5.0. Results · In total, the overall prevalence of DAAs RAVs in NS3 region was high (26.06% and 38.18%, respectively), no matter in genotype 1a or genotype 1b. In genotype 1a, the high prevalence of RAVs mainly presented in the position Q80 (8.45%). In genotype 1b, S122 RAV was most observed(36.36%). It is worth noting that, RAVs in NS5B region were rare observed (0.77%) in this study, especially as no RAV was detected in any sequence of genotype 1a patients. Conclusion · The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients, suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.

Key words: hepatitis C virus, co-infection, direct-acting antiviral agents, resistance associated variants, prevalence

CLC Number: